These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 14696474)

  • 1. Treatment of chronic hepatitis B with high-dose intravenous N-acetyl-L-cysteine.
    Weidenbach H; Orth M; Adler G; Mertens T; Schmid RM
    Hepatogastroenterology; 2003; 50(54):2105-8. PubMed ID: 14696474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
    Stephan C; Berger A; Carlebach A; Lutz T; Bickel M; Klauke S; Staszewski S; Stuermer M
    J Antimicrob Chemother; 2005 Dec; 56(6):1087-93. PubMed ID: 16269552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus-specific T cell response in chronic hepatitis B patients treated with lamivudine and interferon-alpha.
    Pontesilli O; van Nunen AB; van Riel D; Carotenuto P; Niesters HG; Uytdehaag FG; De Man RA; Osterhaus AD
    Liver Int; 2004 Aug; 24(4):308-15. PubMed ID: 15287853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of indomethacin on viral replication markers in asymptomatic carriers of hepatitis B: a randomized, placebo-controlled trial.
    Bahrami H; Daryani NE; Haghpanah B; Moayyeri A; Moghadam KF; Mirmomen S; Kamangar F
    Am J Gastroenterol; 2005 Apr; 100(4):856-61. PubMed ID: 15784032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
    Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
    Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBe-antigen positive hepatitis B patients treated with interferon-alpha.
    van der Eijk AA; Niesters HG; Hansen BE; Heijtink RA; Janssen HL; Schalm SW; de Man RA
    J Viral Hepat; 2006 Feb; 13(2):96-103. PubMed ID: 16436127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. e-antigen-negative chronic hepatitis B in Bangladesh.
    Ahmad N; Alam S; Mustafa G; Adnan AB; Baig RH; Khan M
    Hepatobiliary Pancreat Dis Int; 2008 Aug; 7(4):379-82. PubMed ID: 18693173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients.
    Chang TT; Gish RG; Hadziyannis SJ; Cianciara J; Rizzetto M; Schiff ER; Pastore G; Bacon BR; Poynard T; Joshi S; Klesczewski KS; Thiry A; Rose RE; Colonno RJ; Hindes RG;
    Gastroenterology; 2005 Oct; 129(4):1198-209. PubMed ID: 16230074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of N-acetyl-cysteine on lymphomonocyte glutathione and response to interferon treatment in C-virus chronic hepatitis.
    Cimino L; Belisario MA; Intrieri M; D'Ascoli B; Sacchetti L; Salvatore F; Budillon G
    Ital J Gastroenterol Hepatol; 1998 Apr; 30(2):189-93. PubMed ID: 9675657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.
    Sherman M; Yurdaydin C; Sollano J; Silva M; Liaw YF; Cianciara J; Boron-Kaczmarska A; Martin P; Goodman Z; Colonno R; Cross A; Denisky G; Kreter B; Hindes R;
    Gastroenterology; 2006 Jun; 130(7):2039-49. PubMed ID: 16762627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
    Suzuki Y; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Miyakawa Y; Kumada H
    J Gastroenterol Hepatol; 2009 Mar; 24(3):429-35. PubMed ID: 19226381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study.
    Gish RG; Trinh H; Leung N; Chan FK; Fried MW; Wright TL; Wang C; Anderson J; Mondou E; Snow A; Sorbel J; Rousseau F; Corey L
    J Hepatol; 2005 Jul; 43(1):60-6. PubMed ID: 15922478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virus-specific T cell immune response in children and adolescents with chronic hepatitis B virus infection.
    Fischler B; Nyström J; Björnsdottir T; Lindh G; Hultgren C
    J Pediatr Gastroenterol Nutr; 2007 Jul; 45(1):75-83. PubMed ID: 17592368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B.
    Yuen MF; Kim J; Kim CR; Ngai V; Yuen JC; Min C; Kang HM; Shin BS; Yoo SD; Lai CL
    Antivir Ther; 2006; 11(8):977-83. PubMed ID: 17302367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.
    Yalçin K; Değertekin H; Kokoğlu OF; Ayaz C
    Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
    J Med Virol; 2007 Sep; 79(9):1286-92. PubMed ID: 17607775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy.
    Liaw YF
    Antivir Ther; 2006; 11(6):669-79. PubMed ID: 17310811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study of the relapse of patients with chronic hepatitis B undergoing first and repeated recombinant interferon-alpha therapy during long-term follow up].
    Liu DL; Luo KX; Feng XR; Fu QX; Hou JL
    Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(26):1840-3. PubMed ID: 17922996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of precore mutants during lamivudine treatment in patients with chronic hepatitis B.
    Cheong JY; Cho SW; Yoo JH; Hong SP; Kim SO; Yoo WD; Kim JH
    Hepatogastroenterology; 2008; 55(84):1029-33. PubMed ID: 18705323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.